Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 3/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070435 | 0.86 | ITGB3 (0.46) | ALDH1A1ITGB3ITGA2BALOX15FPR2 | |
| SCHEMBL25188179 | 0.86 | ITGB3 (0.46) | ALDH1A1ITGB3ITGA2BALOX15FPR2 | |
| Hydrochloric Acid SCHEMBL11454643 | 0.85 | ITGB3 (0.46) | ALDH1A1ITGB3ITGA2BALOX15FPR2 | |
| SCHEMBL1216618 | 0.85 | ACE (0.55) | ITGB3ITGA2BACE | |
| SCHEMBL11859682 | 0.84 | PTPN1 (0.52) | ITGB3ITGA2BACEELANE | |
| Hydrochloric Acid SCHEMBL1214885 | 0.84 | ACE (0.54) | ITGB3ITGA2BACE | |
| SCHEMBL11791773 | 0.83 | PPARG (0.53) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL11445317 | 0.82 | ALDH1A1 (0.45) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL11440866 | 0.82 | PPARG (0.52) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL11440858 | 0.82 | PPARG (0.52) | ALDH1A1LMNACYP3A4HIF1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | claimed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | claimed |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| EP-3917504-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | Arizona Board of Regents on behalf of the University of Arizona (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160256-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-06 | — | — | WO | disclosed |
| US-9861600-B2 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment | Arizona Board of Regents, A Body Corporate Of The State Of Arizona Acting For An On Behalf Of The University of Arizona (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| US-9173862-B2 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | Arizona Board of Regents, a body Corporate of the State of Arizona, acting for and on behalf of the (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2273988-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009129497-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS, A BODY CORP. OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-22 | — | — | WO | disclosed |
| US-4065566-A | PRO-DRUG FORM OF L-DOPA, PARKINSON*S DISEASE | INTERX RESEARCH CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3939253-A | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | MTNR1A, MC1R, MTNR1B | ALDH1A1 1215/4885LMNA 2213/4885CYP3A4 4823/4885 |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | MTNR1A, MC1R, MTNR1B | ALDH1A1 1215/4885LMNA 2213/4885CYP3A4 4823/4885 |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | PDE6C, AGER, PDE6D | ALDH1A1 658/4885LMNA 709/4885CYP3A4 4270/4885 |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | PDE6C, PDE6D, AGER | ALDH1A1 874/4885LMNA 740/4885CYP3A4 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.